Navigation Links
BioMarin Announces Second Quarter 2011 Financial Results
Date:7/28/2011

$15

$14 to $18Selected Income Statement Guidance ($ in millions)Item

2011 Guidance

Previous 2011 GuidanceCost of Sales (% of Total Revenue)

Unchanged

18% to 20%Selling, General and Admin. Expense

Unchanged

$164 to $174Research and Development Expense

$200 to $205

$195 to $205Amortization and Contingent Consideration

$2

$15Interest Income

Unchanged

$3Income Tax Expense (Benefit)

$14

$15GAAP Net Income (Loss)

$(43) to $(33)

$(52) to $(42)Stock Compensation Expense

$45

$43Non-GAAP Adjusted EBITDA

$49 to $59

$51 to $61Anticipated Upcoming Milestones3Q 2011/4Q 2011: Top-line results for Phase II trial for PEG-PAL, including daily dosing and formulation studies
1Q 2012/2Q 2012: Initiation of Phase III trial for PEG-PAL
1Q 2012: Initiation of Phase I trial for BMN-111 for Achondroplasia
2H 2012: Top-line results for Phase III trial for GALNS for MPS IVA
2H 2012: Top-line results for PKU-016 Kuvan neurocognitive study
2H 2012: Top-line results for Phase I/II trial for BMN-701 for Pompe disease
4Q 2012/1Q 2013: Market authorization application filings for GALNS for MPS IVA
1Q 2013-3Q 2013: 510k clearance and commercial availability of the handheld blood Phe monitor for PKU

Research and Development ProgramsBioMarin continues to make significant investments in research and development to ensure persistent growth of the company.  The current pipeline includes programs in various stages of development that are focused on treating a range of serious unmet medical needs.Advanced Clinical Programs

  • GALNS for MPS IVA: BioMarin is enrolling patients in the randomized, double-blind, placebo-controlled Phase III study with primary endpoint of six-minute walk distance, 24 weeks in treatment duration and treatment doses of two mg/kg/week and two mg/kg/every other week.  The company exp
    '/>"/>

  • SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
    2. BioMarin Announces FDA Approval for Kuvan
    3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
    4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
    5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
    6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
    7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    8. BioMarin to Present at the Oppenheimer Healthcare Conference
    9. BioMarin Announces Third Quarter 2009 Financial Results
    10. BioMarin to Acquire LEAD Therapeutics
    11. BioMarin to Present at the Credit Suisse Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
    (Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
    (Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
    Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
    ... , LACHEN, Switzerland , Jan. ... of plasma products in the world, today announced that it has received ... Food and Drug Administration (FDA). The approval was granted for the ... bleeding episodes in patients with severe von Willebrand disease (VWD) as well ...
    ... , SUNNYVALE, Calif. , Jan. 13 ... of radiosurgery, today announced that it will report results for its fiscal second ... 4, 2010 after the market closes. , A conference call to review ... EST and will be hosted by Euan S. Thomson , Ph.D., ...
    Cached Medicine Technology:Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 5Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 6Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010 2Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010 3
    (Date:7/9/2014)... poor printing on prescription labels handed out by ... errors in taking medication, according to new research ... National Institute for the Blind)., The study, published ... found that labels on prescription medications dispensed by ... for legibility. , By simply following recommended guidelines ...
    (Date:7/9/2014)... , , , , , ... , , , ... weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , ... , , , , ...
    (Date:7/9/2014)... allergic diseases has risen dramatically in Western societies. One ... to microorganisms and have fewer infections than previous generations, ... study by researchers at Sahlgrenska Academy, University of Gothenburg, ... maturation of the immune system in relation to allergic ... of the Vstra Gtaland Region, half of them on ...
    (Date:7/8/2014)... Older kidney donors enjoy similar longevity and cardiovascular health ... study published in the American Journal of Transplantation ... individuals considering donation and the transplant professionals caring for ... donation by individuals aged 55 years and older has ... kidney disease, and heart disease, the removal of a ...
    (Date:7/8/2014)... Defense Advanced Research Projects Agency (DARPA) awarded Lawrence ... to develop an implantable neural device with the ... brain to help restore memory, DARPA officials announced ... understanding that memory is a process in which ... information, store it and retrieve it. Certain types ...
    Breaking Medicine News(10 mins):Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:Study finds kidney donation safe for healthy older adults 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
    ... New research shows that individual exacerbations in chronic ... of repeat exacerbations, even after five days of ... where each exacerbation can drive the progression of ... are not random has important implication for the ...
    ... JEFFREY KRONSON, M.D. CHALLENGES NOTION THAT CUTTING IS THE ... River,s "Men Are Stupid And They Like Big Boobs" ... effort to coerce women into plastic surgery to be ... remains convinced that younger women and men are getting ...
    ... meet weight-linked healthcare needs of 6.2 million kids , , ... called a "landmark agreement," former President Bill Clinton and ... a national initiative on childhood obesity, aimed at getting ... visits to both primary care physicians and dietitians. , ...
    ... KALAMAZOO, Mich., Feb. 19 Esphera3 International (E3I) ... on the principles of "Patient Focused Care." Currently ... encompasses all aspects of a partnered care health ... resource management and financial operations of healthcare.E3I and ...
    ... 19 Leading Veterans organizations this week ... early lung cancer detection research at the ... strongly supported by the Lung Cancer Alliance ... organizations issue the "Independent Budget" request to ...
    ... There are approximately 7.1 million injury-related emergency department (ED) ... States annually, according to the Centers for Disease Control ... universities, including the University of Missouri, found that young ... to have been reported to Child Protective Services (CPS) ...
    Cached Medicine News:Health News:Exacerbations in COPD: One thing leads to another 2Health News:Exacerbations in COPD: One thing leads to another 3Health News:Joan River's New Plastic Surgery Promotion Book is Out of Sync With What Women Really Need to Hear About Going Under The Knife! 2Health News:Bill Clinton, Health Groups to Tackle Childhood Obesity 2Health News:Esphera3 International Founded on 'Patient Focused Care' 2Health News:Veterans Organizations Call For Early Lung Cancer Detection Research 2Health News:Researchers recommend increased physician awareness to reduce injuries and neglect in children 2
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: